 Home > Active Ingredient News > Antitumor Therapy > Transl Lung Cancer Res: Association of Baseline Tumor Size (BTS) with Outcomes in NSCLC Patients Receiving Immune Monotherapy or Combination Chemotherapy

Transl Lung Cancer Res: Association of Baseline Tumor Size (BTS) with Outcomes in NSCLC Patients Receiving Immune Monotherapy or Combination Chemotherapy

 Last Update: 2022-04-22
 Source: Internet
 Author: User

Tags

number 4 chain

3 5 5 6

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Baseline tumor size (BTS) is a prognostic factor in non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitor monotherapy (ICI-mono)
.

However, in patients receiving ICI plus chemotherapy (ICI-chemo), this relationship is unclear

Baseline tumor size (BTS) is a prognostic factor in non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitor monotherapy (ICI-mono)

This single-center retrospective study evaluated 159 patients with advanced NSCLC who received first-line immune checkpoint inhibitor monotherapy (ICI-mono) or ICI plus chemotherapy (ICI-chemo) from January 2016 to April 2021
.

Imaging assessment was performed according to the evaluation criteria for solid tumor response, and the BTS value was estimated using the longest diameter of the largest target lesion (maxi BTS) and the longest diameter of the total target lesion (total BTS)

The study ultimately included 159 patients, of which 80 (50.

Among patients in the ICI-mono group, median progression-free survival (PFS) was 16.

CBR was higher in the small max BTS group than in the large max BTS group (67.
7% vs.
44.
0%; P = 0.
065)
.

The disease control rate (DCR) was significantly higher in the small max BTS group than in the large max BTS group (83.

CBR was higher in the small max BTS group than in the large max BTS group (67.

Among patients in the ICI-chemo arm, median progression-free survival (PFS) was 7.
8 months (95% CI: 6.
4-14.
3) in the small-max BTS arm and 15.
6 months (95% CI: 6.
3) in the large-max BTS arm -NA), the difference was not statistically significant (P=0.
21)
.

The median PFS in the small total BTS group was 10.

Among patients in the ICI-chemo arm, median progression-free survival (PFS) was 7.

There was no significant difference in CBR between the small and large max BTS groups (77.
6% vs.
80.
1%; P = 1.
00)
.

There was also no significant difference in DCR between the small and large max BTS groups (DCR, 82.

There was no significant difference in CBR between the small and large max BTS groups (77.
6% vs.
80.
1%; P = 1.
00)
.
There was also no significant difference in DCR between the small and large max BTS groups (DCR, 82.
8% vs.
90.
5%; P = 0.
494)
.
There was no significant difference in CBR between the small and large max BTS groups (77.
6% vs.
80.
1%; P = 1.
00)
.
There was also no significant difference in DCR between the small and large max BTS groups (DCR, 82.
8% vs.
90.
5%; P = 0.
494)
.

Among patients with max BTS ≥50 mm, median PFS was 3.
6 months (95% CI: 1.
4-9.
9) in the ICI-mono group and 10.
6 months (95% CI: 6.
5-15.
7) in the ICI-chemo group ( HR: 0.
59; 95%CI: 0.
36 0.
96; P = 0.
032)
.
The median OS in the CI-mono arm was 15.
2 months (95% CI: 9.
3-25.
5), while the median OS in the CI-chemo arm was not reached (HR, 0.
56; 95% CI: 0.
31 1.
04; P = 0.
065)
.
Among patients with PD-L1 TPS ≥ 50%, median PFS was 4.
5 months (95% CI: 2.
1-10.
8) in the ICI-mono arm compared to 15.
7 months (95% CI: 2.
1-10.
8) in the ICI-chemo arm CI: 7.
7 NA) (HR, 0.
38; 95%CI: 0.
14 1.
10; P = 0.
064)
.
Among patients with PD-L1 TPS ≥ 50%, the median OS was 15.
6 months (95% CI: 9.
3 -34.
7) in the CI-mono arm, but not yet in the CI-chemo arm, with no statistical difference (P= 0.
32)
.
Among patients with max BTS ≥50 mm, median PFS was 3.
6 months (95% CI: 1.
4-9.
9) in the ICI-mono group and 10.
6 months (95% CI: 6.
5-15.
7) in the ICI-chemo group ( HR: 0.
59; 95%CI: 0.
36 0.
96; P = 0.
032)
.
The median OS in the CI-mono arm was 15.
2 months (95% CI: 9.
3-25.
5), while the median OS in the CI-chemo arm was not reached (HR, 0.
56; 95% CI: 0.
31 1.
04; P = 0.
065)
.
Among patients with PD-L1 TPS ≥ 50%, median PFS was 4.
5 months (95% CI: 2.
1-10.
8) in the ICI-mono arm compared to 15.
7 months (95% CI: 2.
1-10.
8) in the ICI-chemo arm CI: 7.
7 NA) (HR, 0.
38; 95%CI: 0.
14 1.
10; P = 0.
064)
.
Among patients with PD-L1 TPS ≥ 50%, the median OS was 15.
6 months (95% CI: 9.
3 -34.
7) in the CI-mono arm, but not yet in the CI-chemo arm, with no statistical difference (P= 0.
32)
.

In conclusion, the study showed that large max BTS was a prognostic factor for poorer PFS in patients receiving immunotherapy alone, but not in patients receiving immunocombination chemotherapy
.

In conclusion, the study showed that large max BTS was a prognostic factor for poorer PFS in patients receiving immunotherapy alone, but not in patients receiving immunocombination chemotherapy
.
Studies have shown that high max BTS is a prognostic factor for poorer PFS in patients receiving immunotherapy alone, but not in patients receiving immunocombination chemotherapy
.
Studies have shown that high max BTS is a prognostic factor for poorer PFS in patients receiving immunotherapy alone, but not in patients receiving immunocombination chemotherapy
.

Original source:

Uehara Y, Hakozaki T, Kitadai R, Narita K, Watanabe K, Hashimoto K, Kawai S, Yomota M, Hosomi Y.
Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy.
Transl Lung Cancer Res.
2022 Feb;11(2):135-149.
doi: 10.
21037/tlcr-21-815.
PMID: 35280320; PMCID: PMC8902087.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.